MIRAMIRA PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of MIRA PHARMACEUTICALS, INC. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIRAEsta | $30M#8 | — | 3.7x#12 | — | — | -33.0%#9 | — | -127.9%#10 | — | — | -45.1%#8 | — |
| LITS | $34M#1 | — | 0.6x#4 | — | -100.0%#10 | -189.7%#13 | — | -28.1%#5 | — | — | -62.4%#11 | — |
| FLNA | $33M#2 | — | 0.5x#2 | 0.8x#2 | 277.6%#1 | -273.7%#14 | -232.0%#4 | -133.5%#12 | — | — | -67.5%#13 | — |
| RMTI | $32M#3 | 267.0x#2 | 0.9x#7 | 0.5x#1 | -31.8%#7 | -1007.1%#16 | -6.8%#1 | -15.1%#4 | -14.0%#4 | 4#3 | -52.3%#9 | — |
| BRNS | $31M#4 | — | 0.5x#3 | — | -100.0%#10 | -8.8%#7 | — | -116.4%#9 | — | — | -37.0%#5 | — |
| CPHI | $31M#5 | — | 0.9x#5 | 7.5x#5 | -8.5%#6 | 32.7%#5 | -78.2%#2 | -8.8%#3 | -7.7%#2 | 5#1 | -61.2%#10 | — |
| KYNB | $31M#6 | 0.2x#1 | — | 4.8x#4 | -78.3%#8 | 485.6%#1 | -712.7%#7 | — | — | — | -37.9%#6 | — |
| RNAZ | $31M#7 | — | — | — | — | -106.9%#12 | — | — | — | — | -83.9%#15 | — |
| HEPA | $29M#9 | — | 22.4x#14 | — | — | 37.3%#4 | — | -647.5%#14 | — | — | -17.6%#4 | — |
| APUS | $3M#16 | — | 0.0x#1 | — | — | -331.7%#15 | — | -5.6%#2 | -11.2%#3 | — | -90.1%#16 | — |
| ABVC | $28M#10 | — | 2.7x#10 | 93.2x#8 | 0.0%#4 | -61.3%#11 | -2416.0%#8 | -76.9%#6 | -68.5%#5 | — | -63.6%#12 | — |
| IGC | $28M#11 | — | 4.5x#13 | 21.7x#7 | -5.5%#5 | 45.2%#3 | -585.8%#6 | -116.1%#8 | -125.5%#7 | 3#4 | -38.4%#7 | — |
| NXTC | $27M#12 | — | 2.3x#9 | 1.2x#3 | 252.6%#2 | -0.3%#6 | -257.5%#5 | -459.7%#13 | — | — | 4.6%#2 | — |
| NNVC | $26M#13 | — | 2.9x#11 | — | — | -14.1%#8 | — | -103.4%#7 | -89.9%#6 | — | -16.3%#3 | — |
| TXMD | $25M#14 | — | 0.9x#8 | 8.3x#6 | 71.6%#3 | 73.9%#2 | -145.3%#3 | -2.1%#1 | -3.8%#1 | 5#1 | 91.2%#1 | — |
| ATOS | $25M#15 | — | 0.9x#6 | 13992.6x#9 | -95.6%#9 | -36.3%#10 | -2112684.9%#9 | -129.6%#11 | — | — | -79.9%#14 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice